Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002038579 | SCV002308460 | likely benign | Saldino-Mainzer syndrome | 2025-01-13 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002507824 | SCV002814216 | uncertain significance | Saldino-Mainzer syndrome; Retinitis pigmentosa 80 | 2024-06-17 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV004694153 | SCV005194105 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Institute of Human Genetics, |
RCV004816938 | SCV005068730 | uncertain significance | Retinal dystrophy | 2022-01-01 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004753478 | SCV005347498 | uncertain significance | IFT140-related disorder | 2024-09-16 | no assertion criteria provided | clinical testing | The IFT140 c.481C>A variant is predicted to result in the amino acid substitution p.Pro161Thr. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.025% of alleles in individuals of East Asian descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |